Breaking News

GlycoMimetics Receives $15M Pfizer Milestone

May 21, 2014

Rivipansel moves to Phase III development

GlycoMimetics, Inc. has received a $15 million payment from Pfizer under the companies’ collaboration for the development of rivipansel (GMI-1070). Pfizer plans to initiate a Phase III trial of rivipansel, which will trigger an additional $20 million milestone payment to GlycoMimetics upon dosing of the first patient in the trial.
 
“Moving into Phase III will be a significant step forward in our effort to potentially address the unmet needs of individuals with sickle cell disease. With the commitment of our collaborator, Pfizer, we hope this will enable us to bring to patients, caregivers and physicians an important new medication for treatment of vaso-occlusive crisis or VOC of sickle cell disease,” said Rachel King, chief executive officer, GlycoMimetics.
 
The companies entered the collaboration and exclusive license agreement with for rivipansel in October 2011. The companies are currently developing rivipansel as a potential treatment for VOC of sickle cell disease.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers